Gilead Sciences, Inc. (0QYQ.IL)
| Previous Close | 68.39 |
| Open | 68.33 |
| Bid | 64.83 x N/A |
| Ask | 71.05 x N/A |
| Day's Range | 67.74 - 68.33 |
| 52 Week Range | 62.14 - 87.53 |
| Volume | |
| Avg. Volume | 33,573 |
| Market Cap | 84.916B |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | 15.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.00 (3.81%) |
| Ex-Dividend Date | Sept 14, 2023 |
| 1y Target Est | N/A |
- ACCESSWIRE
Gilead Benefit Helps Employees Navigate Cancer Care
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team. "I was hired at 71 years old. What does ...
- Business Wire
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
FOSTER CITY, Calif., June 20, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.
- ACCESSWIRE
Gilead and Kite Pharma Celebrates Pride Month
NORTHAMPTON, MA / ACCESSWIRE / June 19, 2024 / Gilead Sciences Gilead and Kite Pharma teams raised Pride Month flags at our campuses last week symbolizing our united support for LGBTQ+ communities globally. Our commitment to inclusion and diversity ...
